和厚朴酚通过UbcH8诱导AML1-ETO蛋白降解

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1726 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：研究和厚朴酚诱导AML1-ETO蛋白降解的可能机制。方法：用10、20、40 μmol/L的和厚朴酚处理Kasumi-1细胞，分别在24 h和48 h后qRT-PCR检测AML1-ETO、UbcH8 mRNA的表达；Western blot法检测蛋白表达；40 μmol/L和厚朴酚处理24 h，基因芯片分析寻找靶基因；构建UbcH8过表达质粒，通过反转录病毒转染Kasumi-1细胞，检测AML1-ETO蛋白；通过短发夹RNA（shRNA）敲除UbcH8的表达，40 μmol/L和厚朴酚处理48 h，同时检测AML1-ETO和UbcH8蛋白；构建异种移植小鼠模型，和厚朴酚处理，检测肿瘤的成瘤性和相关蛋白表达。结果：和厚朴酚减少Kasumi-1细胞中AML1-ETO蛋白的表达，并具有浓度和时间依赖性，但没有影响AML1-ETO mRNA的表达；和厚朴酚处理后的AML1-ETO蛋白稳定性降低；基因芯片分析发现，和厚朴酚将UbcH8 mRNA的表达提高了约4倍；和厚朴酚处理后，Kasumi-1细胞中的UbcH8 mRNA和蛋白的表达量均升高；过表达UbcH8的Kasumi-1细胞中，AML1-ETO蛋白表达量减少；用和厚朴酚处理UbcH8敲除后的Kasumi-1细胞，AML1-ETO的降解被阻断；和厚朴酚抑制了异种移植小鼠模型的肿瘤生长，肿瘤中的AML1-ETO蛋白显著降低，而UBCH8表达升高。结论：和厚朴酚能通过UbcH8降解白血病细胞中的AML1-ETO蛋白。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李海英
	周斌
	吴建波
	邢冲云

关键词 ：和厚朴酚, AML1-ETO, UbcH8, 白血病

Abstract：Objective: To investigate the possible mechanism of the degradation of AML1-ETO protein induced by honokiol. Methods: Kasumi-1 cells were treated with 10, 20 and 40 μmol/L honokiol for 24 h and 48 h. The mRNA expression of AML1-ETO and UbcH8 and the protein expression were detected by qRT-PCR and Western blot respectively. Microarry analysis was used to select the target gene. To explore the role of UbcH8 in the degradation of AML1-ETO protein induced by honokiol, the expression of UbcH8 was knocked down by small hairpin RNAs (shRNAs) and overexpressed by MSCV-based vector to detect the related indicators. A xenograft mice model was treated by honokiol to detect tumorigenicity and related protein expression. Results: Honokiol decreased the protein expression of AML1-ETO in a time- and concentration- dependent manner, and reduced the stability of AML1-ETO protein, but did not affect the mRNA expression of AML1-ETO in kasumi-1 cell. We identified UbcH8 as the target gene by honokiol through microarray analysis. Honokiol obviously increased the expression of UbcH8 by 4-fold. Furthermore, overexpression of UbcH8 decreased the expression of AML1-ETO and knockdown of UbcH8 by shRNAs prevented honokiol-induced degradation of AML-ETO, suggesting that UbcH8 plays a critical role in the degradation of AML1-ETO by honokiol. Finally, honokiol decreased xenograft tumor size in a xenograft leukemia mouse model. Meanwhile, the protein of AML1-ETO was significantly reduced, while UBCH8 expression was elevated. Conclusion: Honokiol can degrade AML1-ETO oncoprotein through upregulation of UbcH8 in acute myeloid leukemia.

Key words： honokiol AML1-ETO UbcH8 leukemia

收稿日期: 2019-01-30

基金资助:国家自然科学基金青年基金资助项目（81501809）。

通讯作者: 邢冲云，副主任医师，Email：21182907@qq.com。

作者简介: 李海英（1981-），女，四川遂宁人，主管技师，硕士。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2019/V49/I5/327

[1] OKUDA T, CAI Z, YANG S, et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors[J]. Blood, 1998, 91(9): 3134-3143.
[2] PABST T, MUELLER B U, HARAKAWA N, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t (8; 21) myeloid leukemia [J]. Nat Med, 2001, 7(4): 444-451.
[3] WANG Y Y, ZHAO L J, WU C F, et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice[J]. Proc Natl Acad Sci U S A, 2011, 108(6): 2450-2455.
[4] GRISOLANO J L, ONEAL J, CAIN J, et al. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice [J]. Proc Natl Acad Sci U S A, 2003, 100(16): 9506-9511.
[5] CHEN G, IZZO J, DEMIZU Y, et al. Different redox states in malignant and nonmalignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol[J]. Antioxid Redox Signal, 2009, 11(5): 1083-1095.
[6] AVTANSKI D B, NAGALINGAM A, KUPPUSAMY P, et al. Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-beta-catenin signaling axis in a microRNA-34a dependent manner[J]. Oncotargets, 2015, 6(18): 16396-16410.
[7] PANDEY M K, SUNG B, AGGARWAL B B. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells[J]. Int J Cancer, 2010, 127(2): 282-292.
[8] Bi L, Yu Z, Wu J, et al. Honokiol inhibits constitutive and inducible STAT3 signaling via PU.1-induced SHP1 expression in acute myeloid leukemia cells[J]. Tohoku J Exp Med, 2015, 237(3): 163-172.
[9] SINGH T, GUPTA N A, XU S, et al. Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor[J]. Oncotargets, 2015, 6(25): 21268-21282.
[10] LI H Y, YE H G, CHEN C Q, et al. Honokiol induces cell cycle arrest and apoptosis via inhibiting class I histone deacetylases in acute myeloid leukemia[J]. J Cell Biochem, 2015, 116(2): 287-298.
[11] SERNIWKA S A, SHAW G S. The structure of the UbcH8-ubiquitin complex shows a unique ubiquitin interaction site [J]. Biochemistry, 2009, 48(51): 12169-12179.
[12] MAN N, TAN Y, SUN X J, et al. Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1 dependent manner[J]. Blood, 2017, 129(20): 2782-2792.
[13] LAFIURA K M, EDWARDS H, TAUB J W, et al. Identification and characterization of novel AML1-ETO fusion transcripts in pediatrict (8;21) acute myeloid leukemia: a report from the Children’s Oncology Group[J]. Oncogene, 2008, 27(36): 4933-4942.
[14] 邢冲云, 高申孟, 梁彬, 等. 实时荧光定量PCR检测急性髓系白血病患者WT1基因表达及其临床意义[J]. 温州医学院学报, 2011, 41(6): 527-530.
[15] NISHIDA S, HOSEN N, SHIRAKATA T, et al. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1[J]. Blood, 2006, 107(8): 3303-3312.
[16] ZHAO S, ZHANG Y, SHA K, et al. KRAS (G12D) Cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia[J]. Cell Physiol Biochem, 2014, 33(1): 78-87.
[17] GAO X N, YAN F, LIN J, et al. AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a trans-activation[J]. Leukemia, 2015, 29(8): 1730-1740.
[18] WANG Z, ZHANG X. Chemopreventive activity of honokiol against 7,12-dimethylbenz[a]anthracene-induced mammary cancer in female sprague dawley rats[J]. Front Pharmacol, 2017, 8: 320.
[19] SENGUPTA S, NAGALINGAM A, MUNIRAJ N, et al. Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3[J]. Oncogene, 2017, 36(41): 5709-5721.
[20] PAN J, LEE Y, ZHANG Q, et al. Honokiol decreases lung cancer metastasis through inhibition of the STAT3 signaling pathway[J]. Cancer Prev Res(Phila), 2017, 10(2): 133-141.
[21] LU C H, CHEN S H, CHANG Y S, et al. Honokiol, a potential therapeutic agent, induces cell cycle arrest and program cell death in vitro and in vivo in human thyroid cancer cells[J]. Pharmacol Res, 2017, 115: 288-298.
[22] CHO J H, JEON Y J, PARK S M, et al. Multifunctional effects of honokiol as an anti-inflammatory and anti-cancer drug in human oral squamous cancer cells and xenograft[J]. Biomaterials, 2015, 53: 274-284.
[23] KRAMER O H, MULLER S, BUCHWALD M, et al. Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha[J]. FASEB J, 2008, 22(5): 1369-1379.
[24] TOPALY J, ZELLER W J, FRUEHAUF S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells[J]. Leukemia, 2001, 15(3): 342-347.
[25] HUANG M E, YE Y C, CHEN S R, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leuke-mia[J]. Blood, 1988, 72(2): 567-572.
[26] 陈月苗, 俞康, 郑翠苹, 等. CD56 阳性对急性早幼粒细胞白血病患者预后的影响[J]. 温州医科大学学报, 2019, 49(2): 96-99.